mount
effect
innat
adapt
immun
respons
critic
viral
clearanc
gener
long
last
immun
known
product
inhibitori
factor
may
result
inabl
host
clear
virus
result
chronic
viral
persist
fibrinogenlik
protein
identifi
novel
effector
molecul
regulatori
treg
cell
inhibit
immun
activ
bind
fccriib
express
primarili
antigen
present
cell
apc
studi
show
infect
mice
lymphocyt
choriomening
viru
lcmv
lead
increas
plasma
level
detect
earli
day
postinfect
pi
persist
day
pi
mice
defici
increas
viral
titer
lcmv
liver
earli
pi
clear
viru
day
similar
wild
type
mice
dendrit
cell
dc
isol
spleen
lcmv
infect
increas
express
dc
matur
marker
mhc
class
ii
compar
wild
type
frequenc
cell
produc
ifnc
respons
ex
vivo
peptid
restimul
isol
spleen
lymph
node
also
increas
lcmv
infect
mice
increas
frequenc
cell
specif
lcmv
tetram
gp
np
detect
within
liver
mice
plasma
mice
contain
higher
titer
total
neutral
antilcmv
antibodi
enhanc
antivir
immun
mice
associ
increas
level
serum
alanin
transaminas
alt
hepat
necrosi
inflamm
follow
lcmv
infect
data
demonstr
target
lead
earli
increas
viral
replic
enhanc
antivir
adapt
b
cell
respons
target
may
enhanc
efficaci
current
antivir
therapi
hepatotrop
virus
citat
khattar
r
luft
yavorska
n
shalev
phillip
mj
et
al
target
delet
lead
increas
earli
viral
replic
enhanc
adapt
immun
murin
model
acut
viral
hepat
caus
lcmv
plo
one
viral
hepat
remain
major
caus
human
morbid
mortal
worldwid
lead
caus
primari
liver
cancer
common
indic
liver
transplant
worldwid
follow
infect
hepat
b
viru
hbv
hepat
c
viru
hcv
patient
develop
acut
hepat
may
progress
fulmin
hepat
failur
fhf
small
number
patient
chronic
end
stage
liver
diseas
hepatocellular
carcinoma
hcc
depend
age
infect
immun
statu
host
although
convent
treatment
patient
chronic
hbv
reduc
hepat
activ
diseas
progress
hbv
rare
elimin
lifelong
antivir
therapi
requir
similarli
despit
major
advanc
develop
antivir
therapi
hcv
patient
chronic
infect
hcv
remain
nonrespons
treatment
progress
develop
liver
cirrhosi
hcc
within
year
viral
clearanc
depend
robust
earli
innat
adapt
immun
respons
patient
respond
current
hcv
treatment
appear
reduc
antivir
immun
respons
due
increas
number
activ
treg
cell
suppress
molecul
member
fibrinogenlik
protein
superfamili
recent
identifi
novel
effector
molecul
treg
cell
play
pivot
role
regul
innat
adapt
immun
other
shown
contribut
pathogenesi
number
experiment
human
infecti
diseas
includ
mous
hepat
viru
strain
infect
sever
acut
respiratori
syndrom
sar
hiv
infect
hbv
hcv
infect
mediat
immunosuppress
activ
bind
inhibitori
fccriib
receptor
express
apc
includ
dc
b
cell
inhibit
matur
dc
result
suppress
effector
cell
respons
induc
apoptosi
b
cell
experiment
model
fulmin
hepat
failur
fhf
caus
increas
plasma
level
well
increas
frequenc
treg
preand
infect
shown
predict
diseas
suscept
sever
liver
diseas
inhibit
antibodi
sirna
exon
mous
gene
enhanc
surviv
suscept
anim
wherea
adopt
transfer
wildtyp
treg
resist
mice
acceler
mortal
studi
laboratori
also
suggest
also
involv
pathogenesi
human
chronic
hbv
hcv
infect
previous
demonstr
patient
chronic
hbv
diseas
elev
plasma
level
increas
express
mrna
liver
recent
report
increas
plasma
level
chronic
infect
hcv
patient
associ
increas
sever
liver
diseas
poor
outcom
antivir
therapi
studi
infect
provid
strong
evid
role
pathogenesi
fhf
howev
model
fhf
allow
us
examin
role
adapt
b
cell
antivir
immun
current
studi
util
wellestablish
murin
model
acut
viral
hepat
caus
lcmv
examin
influenc
adapt
b
cell
immun
provid
evid
first
time
play
critic
role
regul
antivir
b
cell
immun
respons
acut
viral
hepat
delet
result
enhanc
dc
matur
well
increas
virusspecif
cell
respons
humor
b
cell
respons
lcmv
collect
data
provid
import
insight
biolog
regul
innat
adapt
antivir
immun
respons
studi
also
underscor
potenti
use
strategi
target
enhanc
viral
clearanc
patient
acut
chronic
hbv
hcv
infect
mice
gener
describ
previous
mice
maintain
background
femal
mice
litterm
control
weigh
gram
maintain
microisol
cage
hous
specif
pathogen
free
spf
condit
anim
coloni
princess
margaret
hospit
univers
toronto
mice
fed
standard
lab
chow
diet
water
ad
libitum
anim
experi
studi
carri
accord
guidelin
set
toronto
gener
research
institut
anim
care
committe
toronto
gener
research
institut
anim
care
committe
approv
studi
lcmv
obtain
gift
laboratori
dr
pamela
ohashi
ontario
cancer
institut
toronto
propag
cell
viru
purifi
viruscontain
supernat
band
isopycn
sigma
aldrich
st
loui
mo
gradient
describ
previous
weightmatch
femal
mice
litterm
control
infect
intraven
pfu
lcmv
viral
titer
measur
liver
tissu
use
focu
form
assay
previous
describ
addit
examin
liver
tissu
pre
post
infect
lcmv
nucleoprotein
immunohistochemistri
previous
describ
lcmv
peptid
gp
b
kavynfatc
np
b
fqpqngqfi
gp
ia
b
glngpdiykgvyqfksvefd
synthes
anaspec
inc
san
jose
ca
puriti
figur
highli
induc
plasma
follow
infect
lcmv
heparin
blood
collect
mice
variou
timepoint
follow
infect
pfu
lcmv
plasma
level
measur
elisa
data
repres
mice
infect
sacrif
timepoint
level
significantli
elev
compar
naiv
uninfect
mice
day
postinfect
statist
signific
assess
use
twoway
anova
degre
hepat
injuri
assess
measur
serum
alt
serum
alt
level
analyz
use
serum
multipl
analyz
johnson
johnson
h
ektachem
dtsc
ii
multianalyz
plasma
level
quantifi
previous
describ
briefli
plate
coat
incub
overnight
ngml
monoclon
captur
antibodi
plasma
sampl
ml
ad
well
follow
hour
incub
wash
tri
buffer
salin
tb
well
incub
mgml
polyclon
rabbit
antibodi
hour
plate
wash
polyclon
bind
detect
secondari
hrpconjug
antirabbit
antibodi
tetrametylbenzidin
tmb
ad
absorb
measur
nm
use
elisa
plate
reader
blood
sampl
collect
post
lcmv
infect
heparin
tube
mous
serum
ifna
measur
perform
use
verikin
mous
interferona
elisa
kit
accord
manufactur
instruct
pbl
interferonsourc
piscataway
nj
spleen
remov
ascept
immers
hank
balanc
salt
solut
hbss
filter
mm
nylon
mesh
cell
treat
rbc
lysi
buffer
ebiosci
san
diego
ca
min
ice
wash
process
assess
matur
statu
dc
spleen
lymph
node
isol
minc
petri
dish
contain
serum
free
rpmi
contain
mgml
collagenas
roch
appli
scienc
indianapoli
mgml
dnase
tissu
digest
uc
min
subsequ
filter
use
mm
nylon
mesh
mononuclear
cell
collect
lympholytem
densiti
centrifug
subject
flow
cytometr
analysi
matur
statu
dc
assess
examin
median
fluoresc
intens
mfi
follow
stain
marker
mhcii
flow
cytometri
liver
infus
inferior
vena
cava
digest
media
serum
free
rpmi
contain
mgml
collagenas
iv
sigma
aldrich
st
loui
mo
mgml
dnase
roch
appli
scienc
indianapoli
rate
mlmin
liver
minc
transfer
petri
dish
contain
digest
media
incub
min
uc
water
bath
reaction
termin
addit
ice
cold
serum
free
rpmi
contain
mm
ethylenediaminetetraacet
acid
edta
sigma
aldrich
st
loui
mo
liver
tissu
filter
use
mm
nylon
mesh
subsequ
centrifug
g
min
supernat
contain
nonparenchym
cell
collect
cell
wash
time
liver
nonparenchym
mononuclear
cell
isol
densiti
centrifug
lympholytem
cedarlan
laboratori
toronto
liver
retriev
infect
uninfect
mice
infus
x
formalin
thermo
fisher
scientif
waltham
massachusett
usa
hour
shake
formalinfix
tissu
submit
patholog
core
facil
toronto
gener
hospit
tissu
embed
paraffin
section
stain
h
e
immunohistochemistri
frozen
section
prepar
embed
right
lobe
liver
optim
cut
temperatur
compound
tissuetek
sakura
finetek
torrenc
ca
fill
cryomold
cryomold
frozen
liquid
nitrogen
process
patholog
core
facil
toronto
gener
hospit
tissu
cut
mm
thick
section
stain
use
rat
antimous
antibodi
clone
ebiosci
san
diego
california
usa
tissu
incub
secondari
antirat
antibodi
conjug
hrp
stain
posit
cell
brown
addit
substrat
dab
zyme
san
francisco
ca
slide
digit
scan
number
cell
quantifi
morphometr
analysi
use
spectrum
aperio
technolog
inc
vista
california
usa
number
cell
express
percent
total
infiltr
mononuclear
cell
antibodi
use
flow
cytometri
follow
antibodi
purchas
ebiosci
san
diego
ca
use
stain
cell
fac
analysi
describ
clone
clone
clone
cell
stain
mononuclear
cell
isol
spleen
inguin
axillari
brachial
lymph
node
liver
wash
suspend
fac
buffer
pb
contain
fc
mm
edta
final
concentr
cellsml
cell
treat
block
nonspecif
bind
fcreceptor
cell
surfac
stain
antibodi
lcmvspecif
tetram
cell
fix
paraformaldehyd
fac
analysi
conduct
use
bd
lsrii
flow
cytomet
data
analyz
use
flowjo
softwar
tree
star
inc
ashland
live
cell
discrimin
accord
forwardscatt
sidescatt
paramet
fixabl
viabil
dye
ebiosci
san
diego
ca
lcmv
elisa
detect
total
lcmv
specif
antibodi
utilis
previous
describ
absorb
valu
measur
nm
correl
captur
total
lcmv
specif
antibodi
within
plasma
sampl
dilut
seri
plasma
sampl
plot
read
dilut
observ
absorb
valu
linear
relationship
one
anoth
sampl
express
fold
increas
absorb
lcmv
neutral
antibodi
titer
quantifi
mous
plasma
plaquereduct
assay
neutral
antibodi
titer
defin
dilut
neutral
plaqu
form
incub
pfu
viru
control
plasma
uninfect
mice
lymphocyt
stimul
mg
mhc
class
irestrict
lcmv
gp
np
peptid
mhc
class
result
report
unless
otherwis
specifi
oneway
twoway
analysi
varianc
anova
use
group
comparison
differ
consid
signific
highli
induc
plasma
mice
follow
infect
lcmv
follow
infect
mice
pfu
lcmv
plasma
level
increas
basal
level
ngml
reach
peak
ngml
day
pi
remain
elev
time
point
studi
day
compar
uninfect
naiv
mice
figur
undetect
plasma
mice
pre
post
lcmv
infect
expect
data
shown
target
delet
lead
enhanc
matur
dc
follow
infect
lcmv
express
level
dc
matur
marker
mhc
class
ii
assess
dc
isol
spleen
lymph
node
lcmvinfect
mice
day
post
lcmv
infect
shown
figur
express
level
mhc
class
ii
dc
mice
significantli
higher
compar
mice
indic
target
delet
lead
increas
activ
dc
follow
infect
lcmv
determin
effect
innat
immun
respons
follow
lcmv
infect
plasma
level
ifna
measur
day
pi
elisa
show
plasma
level
ifna
significantli
higher
mice
compar
mice
indic
target
delet
lead
enhanc
innat
immun
respons
lcmv
infect
figur
examin
effect
develop
antivir
cell
respons
mononuclear
cell
isol
spleen
lymph
node
lcmvinfect
mice
day
pi
follow
vitro
stimul
mononuclear
cell
lcmv
peptid
ifnc
produc
antivir
cell
respons
assess
flow
cytometri
virusspecif
cell
respons
analyz
follow
stimul
lcmvderiv
immunodomin
mhc
class
irestrict
peptid
gp
np
virusspecif
cell
respons
assess
stimul
lcmvderiv
immunodomin
mhc
iirestrict
peptid
gp
shown
figur
day
pi
frequenc
ifnc
produc
cell
significantli
increas
spleen
mice
compar
mice
figur
similar
increas
ifnc
produc
cell
seen
lymph
node
mice
compar
mice
data
shown
examin
effect
develop
antivir
cell
respons
liver
hepat
mononuclear
cell
isol
liver
mice
day
pi
stain
mhc
class
tetram
specif
viral
peptid
epitop
gp
np
target
delet
increas
number
virusspecif
cell
lcmv
epitop
figur
liver
section
infect
mice
also
analyz
presenc
cell
immunostain
quantif
cell
liver
tissu
morphometr
analysi
confirm
frequenc
cell
significantli
greater
mice
compar
mice
day
pi
figur
investig
effect
develop
antivir
b
cell
respons
number
plasma
cell
well
antibodi
respons
analyz
lcmvinfect
mice
number
low
low
plasma
cell
spleen
mice
compar
mice
prior
infect
follow
infect
figur
enhanc
antivir
immun
mice
associ
increas
hepat
necrosi
inflamm
follow
lcmv
infect
alt
level
measur
serum
mice
differ
time
point
post
lcmv
infect
alt
level
significantli
higher
mice
compar
mice
time
point
studi
graph
repres
mice
infect
sacrif
timepoint
statist
signific
assess
use
oneway
anova
b
liver
harvest
mice
variou
time
point
pi
subsequ
stain
h
e
mice
develop
periport
inflamm
day
pi
persist
day
pi
arrow
periport
lobular
inflamm
seen
day
pi
mice
arrow
day
pi
mark
hepat
necrosi
n
inflammatori
infiltr
arrow
seen
within
liver
lobul
resolv
day
pi
arrow
h
e
stain
liver
repres
mice
per
group
time
point
delet
enhanc
antivir
immun
plo
one
wwwplosoneorg
mice
significantli
increas
number
compar
control
mice
figur
titer
total
viru
specif
neutral
antibodi
assess
plasma
mice
day
pi
total
antilcmv
antibodi
respons
greater
mice
compar
mice
timepoint
post
lcmv
infect
figur
titer
neutral
antibodi
undetect
low
mice
timepoint
follow
infect
wherea
mice
develop
clinic
signific
titer
neutral
antibodi
toward
lcmv
earli
week
pi
peak
week
pi
figur
enhanc
antivir
immun
mice
associ
increas
hepat
necrosi
inflamm
follow
lcmv
infect
level
liver
inflammatori
biomark
alt
significantli
higher
serum
mice
compar
mice
time
point
follow
infect
lcmv
figur
liver
histolog
mice
show
increas
number
infiltr
mononuclear
cell
time
point
pi
compar
mice
day
pi
liver
harvest
mice
show
mild
periport
inflamm
persist
day
pi
contrast
liver
section
mice
show
evid
lobular
lymphocyt
infiltr
earli
day
pi
day
pi
exhibit
mark
necroinflammatori
chang
presenc
bridg
necrosi
figur
howev
day
pi
mice
display
normal
liver
architectur
coincid
clearanc
viru
figur
effect
gener
antivir
cell
respons
next
examin
secondari
infect
virusspecif
cell
analyz
spleen
mice
infect
lcmv
day
previous
reinfect
pfu
lcmv
mononuclear
cell
isol
spleen
infect
mice
day
pi
stimul
vitro
class
peptid
gp
np
assess
presenc
antivir
ifnc
cell
respons
follow
secondari
infect
mice
display
higher
frequenc
number
virusspecif
ifnc
cell
compar
mice
time
point
examin
figur
note
viru
could
detect
mice
day
pi
use
lcmv
focu
form
assay
data
shown
target
delet
lead
enhanc
antivir
cell
immun
upon
lcmv
rechalleng
ac
virusspecif
cell
respons
analyz
spleen
mice
infect
lcmv
day
previous
rechalleng
pfu
lcmv
mononuclear
cell
isol
spleen
infect
mice
day
pi
b
stimul
vitro
class
peptid
gp
np
assess
antivir
ifnc
cell
respons
flow
plot
repres
least
mice
per
group
c
graph
show
least
mice
per
group
repres
independ
experi
statist
signific
assess
use
oneway
anova
delet
enhanc
antivir
immun
plo
one
wwwplosoneorg
target
delet
increas
earli
lcmv
viral
replic
viral
replic
markedli
reduc
induct
adapt
immun
evalu
effect
target
delet
liver
viral
titer
lcmv
focu
form
assay
perform
figur
earli
post
infect
prior
develop
adapt
immun
viral
titer
significantli
increas
liver
tissu
mice
compar
mice
reach
maximum
differ
day
pi
howev
day
pi
coincid
develop
adapt
b
cell
immun
respons
liver
viral
titer
mice
significantli
reduc
wherea
continu
rise
mice
figur
day
pi
lcmv
detect
either
mice
liver
section
also
examin
lcmv
nucleoprotein
np
immunostain
lcmv
np
markedli
increas
compar
mice
day
pi
primarili
local
hepatocyt
figur
studi
show
infect
mice
lcmv
lead
increas
plasma
level
detect
earli
day
pi
persist
day
pi
although
mice
earli
increas
viral
titer
lcmv
liver
earli
post
infect
clear
viru
rapid
rate
wild
type
mice
induct
adapt
immun
dendrit
cell
dc
isol
spleen
mice
infect
lcmv
increas
express
dc
matur
marker
mhc
class
ii
compar
wild
type
control
mice
frequenc
ifnc
ifnc
cell
isol
spleen
lymph
node
also
increas
lcmv
infect
mice
increas
frequenc
cell
specif
lcmv
tetram
detect
within
liver
lcmv
infect
mice
plasma
mice
contain
higher
titer
total
neutral
antilcmv
antibodi
enhanc
antivir
immun
mice
associ
increas
level
serum
alt
hepat
necrosi
inflamm
follow
lcmv
figur
target
delet
lead
enhanc
viral
clearanc
kinet
follow
induct
adapt
immun
lcmv
infect
mice
infect
pfu
lcmv
viral
titer
assess
liver
tissu
harvest
variou
timepoint
postinfect
lcmv
focu
form
assay
b
viral
clearanc
kinet
repres
chang
viral
titer
per
day
observ
everi
day
period
follow
infect
c
immunohistochem
stain
np
lcmv
also
util
detect
viru
local
within
liver
day
day
pi
mice
data
repres
least
mice
infect
sacrif
timepoint
statist
signific
assess
use
oneway
anova
repres
imag
shown
immunohistochem
stain
infect
data
demonstr
target
lead
enhanc
antivir
innat
dc
adapt
b
cell
respons
support
target
may
novel
approach
treat
patient
viral
diseas
member
fibrinogenrel
protein
superfamili
shown
integr
compon
innat
adapt
immun
express
surfac
membran
cell
shown
potent
prothrombinas
activ
import
initi
local
fibrin
deposit
prothrombinas
activ
shown
import
contain
viral
spread
previous
other
show
follow
infect
suscept
mice
gener
robust
prothrombinas
respons
result
sinusoid
fibrin
deposit
hepat
necrosi
death
aj
mice
known
resist
gener
significantli
lower
level
mice
clear
viru
recov
mice
fail
gener
procoagul
respons
follow
infect
increas
viral
replic
within
liver
suggest
part
innat
immun
import
limit
viral
replic
earli
spread
prior
develop
adapt
b
cell
antivir
respons
present
studi
also
observ
increas
viral
titer
day
pi
liver
lcmv
infect
mice
prior
develop
adapt
b
cell
immun
respons
agreement
previou
result
studi
infect
lang
et
al
recent
report
kupffer
cell
play
crucial
role
regul
viral
uptak
elimin
show
defect
macrophag
function
associ
widespread
dissemin
lcmv
subsequ
immun
mediat
patholog
result
experi
consist
result
ifna
increas
mice
also
consist
recent
report
teijaro
et
al
show
express
type
interferon
reflect
level
viral
replic
well
interplay
immun
activ
suppress
neg
regul
thu
enhanc
express
type
interferon
seen
consist
enhanc
viral
replic
secondari
loss
express
reticuloendotheli
cell
other
recent
report
put
effector
molecul
treg
cell
potent
immunosuppress
activ
shown
antibodi
complet
block
suppress
activ
treg
cell
restor
effect
cell
respons
consist
target
delet
lead
impair
treg
activ
enhanc
reactiv
dc
b
cell
autoimmun
kidney
diseas
glomerulonephr
note
number
treg
mice
increas
compar
mice
treatment
recombin
inhibit
matur
dc
effector
cell
respons
well
induc
b
cell
apoptosi
mediat
regulatori
effect
bind
inhibitori
fccriib
receptor
express
dc
b
cell
absenc
fccriib
suppress
effect
immun
respons
abrog
base
studi
postul
interfer
inhibitori
pathway
would
enhanc
antivir
immun
innat
adapt
immun
respons
experiment
model
acut
viral
hepat
caus
lcmvwe
examin
effect
develop
adapt
immun
util
model
acut
viral
hepat
caus
lcmv
infect
mice
lcmv
result
acut
selflimit
viral
infect
cellular
humor
immun
respons
known
critic
clearanc
lcmv
apc
present
viral
antigen
cell
lead
gener
viru
specif
cell
lyse
viral
infect
cell
viru
specif
cell
produc
immunostimulatori
cytokin
ifnc
cell
also
provid
necessari
signal
stimul
secret
protect
neutral
antibodi
lcmv
b
cell
recent
studi
report
contribut
treg
impair
cell
respons
lcmv
modul
dc
activ
follow
infect
pfu
lcmv
observ
enhanc
activ
dc
mice
earli
day
pi
shown
increas
express
matur
marker
mhcii
isol
cell
increas
plasma
ifna
level
result
consist
previou
studi
laboratori
show
uninfect
mice
increas
express
matur
marker
dc
deriv
bonemarrow
spleen
propos
increas
matur
dc
earli
stage
infect
contribut
augment
antivir
cell
respons
compar
mice
increas
frequenc
intrahepat
cell
virusspecif
cell
found
mice
infect
lcmv
addit
increas
frequenc
virusspecif
cell
loss
enhanc
ifnc
respons
ctl
thelper
cell
upon
vitro
stimul
lcmv
peptid
present
studi
also
shown
regul
humor
immun
post
infect
lcmv
mice
increas
number
low
low
plasma
cell
well
increas
titer
total
lcmv
specif
lcmv
neutral
antibodi
wherea
mice
fail
mount
effect
b
cell
respons
even
long
viral
clearanc
previous
report
effect
loss
gener
secondari
cell
immun
respons
lcmv
also
examin
mice
mice
reinfect
lcmv
day
post
primari
infect
higher
frequenc
viru
specif
cell
earli
day
post
reinfect
indic
robust
secondari
antivir
immun
respons
reinfect
lcmv
mice
compar
mice
coincid
enhanc
adapt
b
cell
antilcmv
immun
respons
mice
lack
increas
hepatocyt
necrosi
shown
biochem
alt
histolog
marker
liver
injuri
well
reduct
viral
titer
day
pi
compar
mice
enhanc
adapt
immun
seen
mice
day
pi
may
secondari
earli
enhanc
viral
replic
occur
consequ
loss
prothrombinas
enhanc
viral
replic
seen
agreement
data
laboratori
other
shown
part
earli
innat
immun
respons
limit
viral
replic
spread
altern
explan
enhanc
adapt
immun
respons
loss
treg
suppress
effector
shown
number
investig
enhanc
adapt
immun
time
determin
unequivoc
whether
loss
prothrombinas
associ
increas
viral
replic
loss
immunosuppress
produc
treg
account
increas
adapt
b
cell
antivir
immun
seen
furthermor
report
high
level
lcmv
viru
result
reduct
ctl
antibodi
respons
increas
express
immunosuppress
cytokin
lead
cell
exhaust
thu
data
collect
would
support
increas
adapt
b
cell
antivir
immun
secondari
loss
suppress
treg
activ
rather
increas
viral
replic
secondari
loss
prothrombinas
conclus
data
present
studi
demonstr
target
lead
enhanc
antivir
adapt
b
cell
respons
may
use
alon
enhanc
efficaci
current
antivir
therapi
hepatotrop
virus
